Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tracks how Gene-Targeted combo therapy fights tough lung cancers

NCT ID NCT06494540

Recruiting now Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025

Summary

This study follows 600 adults in Germany with a type of advanced lung cancer that has spread. They are receiving a combination of two immunotherapy drugs (tremelimumab and durvalumab) plus chemotherapy as their first treatment. The goal is to see how well this treatment works in people whose tumors have certain genetic changes, like KRAS or STK11 mutations. The study does not give any new treatment—it simply collects real-world data to help doctors choose the best therapy for each patient.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SQUAMOUS METASTATIC NON-SMALL-CELL LUNG CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Research Site

    RECRUITING

    Koln-Mehrheim, Germany

  • Research Site

    RECRUITING

    Mainz, Germany

  • Research Site

    RECRUITING

    Bad Homburg, Germany

  • Research Site

    RECRUITING

    Berlin, Germany

  • Research Site

    RECRUITING

    Bremen, Germany

  • Research Site

    WITHDRAWN

    Celle, Germany

  • Research Site

    RECRUITING

    Chemnitz, Germany

  • Research Site

    RECRUITING

    Cologne, Germany

  • Research Site

    RECRUITING

    Deggendorf, Germany

  • Research Site

    RECRUITING

    Frankfurt, Germany

  • Research Site

    RECRUITING

    Georgsmarienhütte, Germany

  • Research Site

    WITHDRAWN

    Gera, Germany

  • Research Site

    RECRUITING

    Goslar, Germany

  • Research Site

    RECRUITING

    Greifswald, Germany

  • Research Site

    RECRUITING

    Halle-Dolau, Germany

  • Research Site

    RECRUITING

    Hanover, Germany

  • Research Site

    RECRUITING

    Herne, Germany

  • Research Site

    RECRUITING

    Hösbach, Germany

  • Research Site

    RECRUITING

    Marburg, Germany

  • Research Site

    RECRUITING

    Münnerstadt, Germany

  • Research Site

    RECRUITING

    Neuss, Germany

  • Research Site

    RECRUITING

    Offenbach, Germany

  • Research Site

    RECRUITING

    Querfurt, Germany

  • Research Site

    RECRUITING

    Ravensburg, Germany

  • Research Site

    RECRUITING

    Rüsselsheim am Main, Germany

  • Research Site

    RECRUITING

    Treuenbrietzen, Germany

  • Research Site

    RECRUITING

    Ulm, Germany

  • Research Site

    RECRUITING

    Wiesbaden, Germany

  • Research Site

    RECRUITING

    Zwickau, Germany

Conditions

The condition(s) this trial relates to.

hereditary sensory and autonomic neuropathy non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SQUAMOUS METASTATIC NON-SMALL-CELL LUNG CARCINOMA